Polypharmacy in elderly patients with cancer: clinical implications and management

被引:198
作者
Lees, Judith [1 ]
Chan, Alexandre [2 ,3 ]
机构
[1] Royal Adelaide Hosp, Ctr Canc, Adelaide, SA 5000, Australia
[2] Natl Univ Singapore, Fac Sci, Dept Pharm, Singapore 117548, Singapore
[3] Natl Canc Ctr, Singapore, Singapore
关键词
DRUG-DRUG INTERACTIONS; MEDICATION HISTORIES; HOSPITAL ADMISSIONS; INTERACTION ALERTS; ONCOLOGY; PHARMACIST; OLDER; QUALITY; COMPLEMENTARY; CHEMOTHERAPY;
D O I
10.1016/S1470-2045(11)70040-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
More and more elderly people with cancer are treated in oncology clinics worldwide every year, many of whom have comorbid disorders treated with one or more drugs. Moreover, these patients might also take self-prescribed over-the-counter drugs or complementary and alternative medicines, which they might not tell their doctor about. Initiation of chemotherapy with one or more cytotoxic or targeted agents and drugs for treatment of cancer symptoms or toxic effects related to treatment can result in polypharmacy. We examine the clinical implications of polypharmacy. Challenges for the medical teams who treat elderly patients with cancer include identification of what drugs are actually being taken by the patient, avoidance or management of any adverse effects or drug interactions, and reassessing the patient's overall treatment. We address these issues and propose practical recommendations for management of treatment for elderly patients with cancer.
引用
收藏
页码:1249 / 1257
页数:9
相关论文
共 60 条
[1]  
[Anonymous], NAT CANC I ONL DICT
[2]  
[Anonymous], 2011, US NAT COMPR CANC NE
[3]   Warfarin Interactions With Substances Listed in Drug Information Compendia and in the FDA-Approved Label for Warfarin Sodium [J].
Anthony, M. ;
Romero, K. ;
Malone, D. C. ;
Hines, L. E. ;
Higgins, L. ;
Woosley, R. L. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (04) :425-429
[4]   Discontinuing medications: A novel approach for revising the prescribing stage of the medication-use process [J].
Bain, Kevin T. ;
Holmes, Holly M. ;
Beers, Mark H. ;
Maio, Vittorio ;
Handler, Steven M. ;
Pauker, Stephen G. .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2008, 56 (10) :1946-1952
[5]   Drug interactions in oncology [J].
Beijnen, JH ;
Schellens, JHM .
LANCET ONCOLOGY, 2004, 5 (08) :489-496
[6]   Drug-drug interactions in oncology: Why are they important and can they be minimized? [J].
Blower, P ;
de Wit, R ;
Goodin, S ;
Aapro, M .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 55 (02) :117-142
[7]   Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer [J].
Camidge, R ;
Reigner, B ;
Cassidy, J ;
Grange, S ;
Abt, M ;
Weidekamm, E ;
Jodrell, D .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (21) :4719-4725
[8]  
Cancer Research UK, DEM FACTS WORLD POP
[9]   Pharmacist-acquired medication histories in a university hospital emergency department [J].
Carter, Melinda K. ;
Allin, Dennis M. ;
Scott, Leigh Anne ;
Grauer, Dennis .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2006, 63 (24) :2500-2503
[10]   The treatment of co-morbidities in older patients with metastatic cancer [J].
Cashman, Josephine ;
Wright, Juliet ;
Ring, Alistair .
SUPPORTIVE CARE IN CANCER, 2010, 18 (05) :651-655